<DOC>
	<DOCNO>NCT02926872</DOCNO>
	<brief_summary>The primary outcome study development clinical profile pediatric patient LAL-D , enable Sponsor provide focus guidance medical community pediatric patient test LAL-D .</brief_summary>
	<brief_title>Screening Lysosomal Acid Lipase Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Wolman Disease</mesh_term>
	<criteria>1 . Male female patient ≥ 2 ≤ 16 year age date inform consent . ( Note : Female patient childbearing potential pregnant may participate study . ) 2 . Patient patient 's parent legal guardian ( applicable ) consent participation study . If patient minor age , he/she willing provide assent require per local regulation , deem able . 3 . Patient meet component Criterion A and/or Criterion B . Criterion A : Patient dyslipidemia , define least one follow lipid abnormality base local laboratory result obtain within 3 month prior date inform consent ( screen visit , applicable ) : LDLc ≥ 130 mg/dL HDL c ≤ 40 mg/dL ( male patient ) ≤ 50 mg/dL ( female patient ) Note : For patient receive lipidlowering medication ( LLM ) , patient must stable dose LLM least 4 week prior serum lipid result . AND Patient least one follow liver spleen abnormality : Hepatomegaly , determine investigator base physical examination image procedure ; Splenomegaly , determine investigator base physical examination image procedure ; ALT &gt; 75 U/L ALT &gt; 1.5x upper limit normal ( ULN ) ( base age genderspecific normal range local laboratory perform assay ) within 3 month prior date inform consent ( screen visit , applicable ) . Criterion B : Patient steatosis ( microvesicular mixed macro/microvesicular ) , hepatic fibrosis , and/or cirrhosis unknown etiology , determine liver biopsy perform within previous 3 year . ( Note : For patient receive liver transplantation , liver biopsy result must obtain prior date liver transplantation . ) 1 . Patient confirm cause liver disease LALD . 2 . Patient genetically confirm heterozygous familial hypercholesteremia secondary cause hypercholesterolemia . 3 . Patient current evidence neurological dysfunction and/or history neurological dysfunction within one year prior date informed consent . 4 . Patient previously screen LALD find normal enzyme activity base reference range laboratory perform assay . 5 . Patient currently receive treatment sebelipase alfa ( Kanuma ) previously participate clinical study sebelipase alfa ( Kanuma ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Screening</keyword>
	<keyword>Hepatic Injury</keyword>
	<keyword>Pediatric Patients</keyword>
</DOC>